{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:45:05Z","timestamp":1787168705322,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T00:00:00Z","timestamp":1534464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T00:00:00Z","timestamp":1534464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1038\/s41380-018-0203-5","type":"journal-article","created":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T04:39:45Z","timestamp":1534480785000},"page":"2608-2619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["18F-FIBT may expand PET for \u03b2-amyloid imaging in neurodegenerative diseases"],"prefix":"10.1038","volume":"25","author":[{"given":"Timo","family":"Grimmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuangyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Diehl-Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Natale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Drzezga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"F\u00f6rster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"F\u00f6rstl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Schwaiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Yakushev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00fcrgen","family":"Wester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kurz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0679-4449","authenticated-orcid":false,"given":"Behrooz Hooshyar","family":"Yousefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,17]]},"reference":[{"key":"203_CR1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science. 2002;297:353\u20136.","journal-title":"Science"},{"key":"203_CR2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA. Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science. 1992;256:184\u20135.","journal-title":"Science"},{"key":"203_CR3","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306\u201319.","journal-title":"Ann Neurol"},{"key":"203_CR4","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313:1924\u201338.","journal-title":"JAMA"},{"key":"203_CR5","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1001\/jama.2015.4669","volume":"313","author":"R Ossenkoppele","year":"2015","unstructured":"Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313:1939\u201349.","journal-title":"JAMA"},{"key":"203_CR6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1021\/ml200123w","volume":"2","author":"BH Yousefi","year":"2011","unstructured":"Yousefi BH, Drzezga A, von Reutern B, Manook A, Schwaiger M, Wester HJ, et al. A Novel 18F-labeled imidazo[2,1-b]benzothiazole (IBT) for high-contrast PET imaging of \u03b2-amyloid plaques. ACS Med Chem Lett. 2011;2:673\u20137.","journal-title":"ACS Med Chem Lett"},{"key":"203_CR7","doi-asserted-by":"crossref","DOI":"10.1186\/s13550-015-0090-6","volume":"5","author":"BH Yousefi","year":"2015","unstructured":"Yousefi BH, von Reutern B, Scherubl D, Manook A, Schwaiger M, Grimmer T, et al. FIBT versus florbetaben and PiB: a preclinical comparison study with amyloid-PET in transgenic mice. EJNMMI Res. 2015;5:20.","journal-title":"EJNMMI Res"},{"key":"203_CR8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1021\/cn5001827","volume":"6","author":"BH Yousefi","year":"2015","unstructured":"Yousefi BH, Manook A, Grimmer T, Arzberger T, von Reutern B, Henriksen G, et al. Characterization and first human investigation of FIBT, a novel fluorinated Abeta plaque neuroimaging PET radioligand. ACS Chem Neurosci. 2015;6:428\u201337.","journal-title":"ACS Chem Neurosci"},{"key":"203_CR9","first-page":"57","volume":"28","author":"SC Huang","year":"2008","unstructured":"Huang SC. Role of kinetic modeling in biomedical imaging. J Med Sci. 2008;28:57\u201363.","journal-title":"J Med Sci"},{"key":"203_CR10","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00004647-200106000-00002","volume":"21","author":"RN Gunn","year":"2001","unstructured":"Gunn RN, Gunn SR, Cunningham VJ. Positron emission tomography compartmental models. J Cereb Blood Flow Metab. 2001;21:635\u201352.","journal-title":"J Cereb Blood Flow Metab"},{"key":"203_CR11","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/sj.jcbfm.9600146","volume":"25","author":"JC Price","year":"2005","unstructured":"Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25:1528\u201347.","journal-title":"J Cereb Blood Flow Metab"},{"key":"203_CR12","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.neuroimage.2007.03.004","volume":"36","author":"Y Zhou","year":"2007","unstructured":"Zhou Y, Resnick SM, Ye W, Fan H, Holt DP, Klunk WE, et al. Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer\u2019s disease. Neuroimage. 2007;36:298\u2013312.","journal-title":"Neuroimage"},{"key":"203_CR13","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2967\/jnumed.113.133793","volume":"55","author":"H Ito","year":"2014","unstructured":"Ito H, Shimada H, Shinotoh H, Takano H, Sasaki T, Nogami T, et al. Quantitative analysis of amyloid deposition in Alzheimer disease Using PET and the radiotracer (1)(1)C-AZD2184. J Nucl Med. 2014;55:932\u20138.","journal-title":"J Nucl Med"},{"key":"203_CR14","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/jcbfm.1990.127","volume":"10","author":"J Logan","year":"1990","unstructured":"Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740\u20137.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"3 Pt 1","key":"203_CR15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/nimg.1996.0066","volume":"4","author":"AA Lammertsma","year":"1996","unstructured":"Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4(3 Pt 1):153\u20138.","journal-title":"Neuroimage"},{"key":"203_CR16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1006\/nimg.1997.0303","volume":"6","author":"RN Gunn","year":"1997","unstructured":"Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage. 1997;6:279\u201387.","journal-title":"Neuroimage"},{"key":"203_CR17","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.neuroimage.2009.05.099","volume":"47","author":"Y Ikoma","year":"2009","unstructured":"Ikoma Y, Watabe H, Hayashi T, Miyake Y, Teramoto N, Minato K, et al. Quantitative evaluation of changes in binding potential with a simplified reference tissue model and multiple injections of [11C]raclopride. Neuroimage. 2009;47:1639\u201348.","journal-title":"Neuroimage"},{"key":"203_CR18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00004647-199601000-00005","volume":"16","author":"AA Lammertsma","year":"1996","unstructured":"Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ, et al. Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab. 1996;16:42\u201352.","journal-title":"J Cereb Blood Flow Metab"},{"key":"203_CR19","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2967\/jnumed.112.107185","volume":"54","author":"GA Becker","year":"2013","unstructured":"Becker GA, Ichise M, Barthel H, Luthardt J, Patt M, Seese A, et al. PET quantification of 18F-florbetaben binding to beta-amyloid deposits in human brains. J Nucl Med. 2013;54:723\u201331.","journal-title":"J Nucl Med"},{"key":"203_CR20","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/jcbfm.2014.202","volume":"35","author":"CA Salinas","year":"2015","unstructured":"Salinas CA, Searle GE, Gunn RN. The simplified reference tissue model: model assumption violations and their impact on binding potential. J Cereb Blood Flow Metab. 2015;35:304\u201311.","journal-title":"J Cereb Blood Flow Metab"},{"key":"203_CR21","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/00004647-199609000-00008","volume":"16","author":"J Logan","year":"1996","unstructured":"Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834\u201340.","journal-title":"J Cereb Blood Flow Metab"},{"key":"203_CR22","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00259-009-1293-8","volume":"37","author":"KP Wong","year":"2010","unstructured":"Wong KP, Wardak M, Shao W, Dahlbom M, Kepe V, Liu J, et al. Quantitative analysis of [18F]FDDNP PET using subcortical white matter as reference region. Eur J Nucl Med Mol Imaging. 2010;37:575\u201388.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"203_CR23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.111.094029","volume":"53","author":"Z Cselenyi","year":"2012","unstructured":"Cselenyi Z, Jonhagen ME, Forsberg A, Halldin C, Julin P, Schou M, et al. Clinical validation of 18F-AZD4694, an amyloid-beta-specific PET radioligand. J Nucl Med. 2012;53:415\u201324.","journal-title":"J Nucl Med"},{"key":"203_CR24","doi-asserted-by":"crossref","first-page":"7081","DOI":"10.1088\/0031-9155\/58\/20\/7081","volume":"58","author":"SL Bowen","year":"2013","unstructured":"Bowen SL, Byars LG, Michel CJ, Chonde DB, Catana C. Influence of the partial volume correction method on (18)F-fluorodeoxyglucose brain kinetic modelling from dynamic PET images reconstructed with resolution model based OSEM. Phys Med Biol. 2013;58:7081\u2013106.","journal-title":"Phys Med Biol"},{"key":"203_CR25","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.neuroimage.2016.09.028","volume":"143","author":"K Matsubara","year":"2016","unstructured":"Matsubara K, Ibaraki M, Shimada H, Ikoma Y, Suhara T, Kinoshita T, et al. Impact of spillover from white matter by partial volume effect on quantification of amyloid deposition with [11C]PiB PET. Neuroimage. 2016;143:316\u201324.","journal-title":"Neuroimage"},{"key":"203_CR26","doi-asserted-by":"crossref","first-page":"R119","DOI":"10.1088\/0031-9155\/57\/21\/R119","volume":"57","author":"K Erlandsson","year":"2012","unstructured":"Erlandsson K, Buvat I, Pretorius PH, Thomas BA, Hutton BF. A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology. Phys Med Biol. 2012;57:R119\u201359.","journal-title":"Phys Med Biol"},{"key":"203_CR27","doi-asserted-by":"crossref","first-page":"78","DOI":"10.2967\/jnumed.115.154757","volume":"57","author":"B Aklan","year":"2016","unstructured":"Aklan B, Oehmigen M, Beiderwellen K, Ruhlmann M, Paulus DH, Jakoby BW, et al. Impact of point-spread function modeling on PET image quality in integrated PET\/MR hybrid imaging. J Nucl Med. 2016;57:78\u201384.","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"203_CR28","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1007\/s00259-008-1007-7","volume":"36","author":"M Hofmann","year":"2009","unstructured":"Hofmann M, Pichler B, Scholkopf B, Beyer T. Towards quantitative PET\/MRI: a review of MR-based attenuation correction techniques. Eur J Nucl Med Mol Imaging. 2009;36(Suppl 1):S93\u2013104.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"203_CR29","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1212\/WNL.39.9.1159","volume":"39","author":"JC Morris","year":"1989","unstructured":"Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, et al. The Consortium to establish a registry for Alzheimer\u2019s disease (CERAD). part i. clinical and neuropsychological assessment of Alzheimer\u2019s disease. Neurology. 1989;39:1159\u201365.","journal-title":"Neurology"},{"key":"203_CR30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \u201cMini-mental state\u201d. a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189\u201398.","journal-title":"J Psychiatr Res"},{"key":"203_CR31","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412\u20134.","journal-title":"Neurology"},{"key":"203_CR32","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.2967\/jnumed.111.092726","volume":"52","author":"G Delso","year":"2011","unstructured":"Delso G, Furst S, Jakoby B, Ladebeck R, Ganter C, Nekolla SG, et al. Performance measurements of the Siemens mMR integrated whole-body PET\/MR scanner. J Nucl Med. 2011;52:1914\u201322.","journal-title":"J Nucl Med"},{"key":"203_CR33","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2967\/jnumed.111.098608","volume":"53","author":"A Drzezga","year":"2012","unstructured":"Drzezga A, Souvatzoglou M, Eiber M, Beer AJ, Furst S, Martinez-Moller A, et al. First clinical experience with integrated whole-body PET\/MR: comparison to PET\/CT in patients with oncologic diagnoses. J Nucl Med. 2012;53:845\u201355.","journal-title":"J Nucl Med"},{"key":"203_CR34","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/jcbfm.1992.81","volume":"12","author":"HW Muller-Gartner","year":"1992","unstructured":"Muller-Gartner HW, Links JM, Prince JL, Bryan RN, McVeigh E, Leal JP, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab. 1992;12:571\u201383.","journal-title":"J Cereb Blood Flow Metab"},{"key":"203_CR35","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1006\/nimg.2001.0978","volume":"15","author":"N Tzourio-Mazoyer","year":"2002","unstructured":"Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273\u201389.","journal-title":"Neuroimage"},{"key":"203_CR36","doi-asserted-by":"crossref","first-page":"e0152082","DOI":"10.1371\/journal.pone.0152082","volume":"11","author":"Y Su","year":"2016","unstructured":"Su Y, Blazey TM, Owen CJ, Christensen JJ, Friedrichsen K, Joseph-Mathurin N, et al. Quantitative amyloid imaging in autosomal dominant Alzheimer\u2019s disease: results from the DIAN Study Group. PLoS ONE. 2016;11:e0152082.","journal-title":"PLoS ONE"},{"key":"203_CR37","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.neuroimage.2014.11.055","volume":"108","author":"M Brendel","year":"2015","unstructured":"Brendel M, Hogenauer M, Delker A, Sauerbeck J, Bartenstein P, Seibyl J, et al. Improved longitudinal [(18)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction. Neuroimage. 2015;108:450\u20139.","journal-title":"Neuroimage"},{"key":"203_CR38","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2967\/jnumed.114.149732","volume":"56","author":"K Chen","year":"2015","unstructured":"Chen K, Roontiva A, Thiyyagura P, Lee W, Liu X, Ayutyanont N, et al. Improved power for characterizing longitudinal amyloid-beta PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med. 2015;56:560\u20136.","journal-title":"J Nucl Med"},{"key":"203_CR39","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2967\/jnumed.114.148981","volume":"56","author":"SM Landau","year":"2015","unstructured":"Landau SM, Fero A, Baker SL, Koeppe R, Mintun M, Chen K, et al. Measurement of longitudinal beta-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med. 2015;56:567\u201374.","journal-title":"J Nucl Med"},{"key":"203_CR40","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.2967\/jnumed.114.153494","volume":"56","author":"AD Joshi","year":"2015","unstructured":"Joshi AD, Pontecorvo MJ, Lu M, Skovronsky DM, Mintun MA, Devous MD, et al. for Quantification of F 18 Florbetapir PET Images. J Nucl Med. 2015;56:1736\u201341.","journal-title":"J Nucl Med"},{"key":"203_CR41","doi-asserted-by":"crossref","first-page":"6553","DOI":"10.1158\/1078-0432.CCR-10-3290","volume":"17","author":"M Wardak","year":"2011","unstructured":"Wardak M, Schiepers C, Dahlbom M, Cloughesy T, Chen W, Satyamurthy N, et al. Discriminant analysis of (1)F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma. Clin Cancer Res. 2011;17:6553\u201362.","journal-title":"Clin Cancer Res"},{"key":"203_CR42","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.2967\/jnumed.115.171652","volume":"57","author":"AM Catafau","year":"2016","unstructured":"Catafau AM, Bullich S, Seibyl JP, Barthel H, Ghetti B, Leverenz J, et al. Cerebellar amyloid-beta plaques: How frequent are they, and do they influence 18F-Florbetaben SUVR? J Nucl Med. 2016;57:1740\u20135.","journal-title":"J Nucl Med"},{"key":"203_CR43","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.neurobiolaging.2008.01.016","volume":"30","author":"T Grimmer","year":"2009","unstructured":"Grimmer T, Henriksen G, Wester HJ, Forstl H, Klunk WE, Mathis CA, et al. Clinical severity of Alzheimer\u2019s disease is associated with PIB uptake in PET. Neurobiol Aging. 2009;30:1902\u20139.","journal-title":"Neurobiol Aging"},{"key":"203_CR44","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.nicl.2015.10.007","volume":"9","author":"JM Mountz","year":"2015","unstructured":"Mountz JM, Laymon CM, Cohen AD, Zhang Z, Price JC, Boudhar S, et al. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer\u2019s subjects. NeuroImage Clin. 2015;9:592\u20138.","journal-title":"NeuroImage Clin"},{"key":"203_CR45","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1007\/s00259-011-1821-1","volume":"38","author":"H Barthel","year":"2011","unstructured":"Barthel H, Luthardt J, Becker G, Patt M, Hammerstein E, Hartwig K, et al. Individualized quantification of brain beta-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer\u2019s disease and healthy controls. Eur J Nucl Med Mol Imaging. 2011;38:1702\u201314.","journal-title":"Eur J Nucl Med Mol Imaging"}],"updated-by":[{"DOI":"10.1038\/s41380-018-0302-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T00:00:00Z","timestamp":1542758400000}}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-018-0203-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-018-0203-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-018-0203-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T10:41:56Z","timestamp":1721904116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-018-0203-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,17]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["203"],"URL":"https:\/\/doi.org\/10.1038\/s41380-018-0203-5","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,17]]},"assertion":[{"value":"16 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41380-018-0302-3","URL":"https:\/\/doi.org\/10.1038\/s41380-018-0302-3","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"TG reported having received consulting fees from Actelion, Biogen, Lilly, MSD; Novartis, Quintiles, Roche Pharma; lecture fees from B. Braun, Biogen, Lilly, Parexel, Roche Pharma, and grants to his institution from Actelion and PreDemTech. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}